March 1, 2022
PA-20-185 - NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed)
PA-20-183 - NIH Research Project Grant (Parent R01 Clinical Trial Required)
PA-20-200 - NIH Small Research Grant Program (Parent R03 Clinical Trial Not Allowed)
PA-20-195 - NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Not Allowed)
PA-20-194 - NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Required)
PA-20-272 - Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp - Clinical Trial Optional)
PA-20-022 - Research Supplements to Promote Diversity in Health-Related Research (Admin Supp - Clinical Trial Not Allowed)
National Institute on Drug Abuse (NIDA)
This Notice encourages research projects that 1) leverage data science to provide actionable insights for substance use prevention and treatment, 2) shorten the time between data capture and data availability so that data are available real-time or near real-time, and 3) explore methods and tools that may allow for faster or better localized responses for substance use treatment and prevention. Priority will be given to projects that emphasize the use of existing data streams (e.g., electronic health records, syndromic surveillance, claims data, registry data, pharmacy dispensing, social media, and mortality records).
Collaborations among multiple disciplines are encouraged for this Notice. Priority will be given to applications that demonstrate the involvement and support of community-based stakeholders and other end-users (e.g., clinicians, patients, parents, public health professionals, patient representatives) along the research continuum.
Individuals from diverse backgrounds, including those from groups historically underrepresented in the STEM fields, who wish to pursue further studies or careers in data science as it relates to addiction research are highly encouraged to apply.
A significant time lag in translating health research to practice, policy, and population health has been a well-recognized challenge in public health. Additional research is needed that leverages data science to provide timely data-driven insights that inform planning, decision-making, and assessment of population-wide interventions in prevention and treatment settings and to advance precision public health to deliver the right intervention to the right people at the right time.
NIH defines data science as “the interdisciplinary field of inquiry in which quantitative and analytical approaches, processes, and systems are developed and used to extract knowledge and insights from increasingly large and/or complex sets of data.”
NIDA is interested in applications that leverage data science to advance translation of science to inform drug misuse epidemiology and etiology that can lead to actionable insights. Of particular interest are projects that explore methods, approaches, and/or tools to facilitate the availability, accuracy, and timeliness of data sources that could provide novel insights into substance use prevention and treatment near real-time or real-time, and projects that propose to develop methods and tools for small area estimation to inform decisions of local (e.g., substate) jurisdictions.
Research projects that could be addressed in response to this NOSI include, but are not limited to, the following:
Prospective applicants are encouraged to contact the NIDA program staff listed below to ensure that the proposed aims are consistent with NIDA’s mission.
Application and Submission Information
This notice applies to due dates on or after June 5, 2022 and subsequent receipt dates through September 8, 2025.
Submit applications for this initiative using one of the following funding opportunity announcements (FOAs) or any reissues of these announcement through the expiration date of this notice.
All instructions in the SF424 (R&R) Application Guide and the funding opportunity announcement used for submission must be followed, with the following additions:
Applications nonresponsive to terms of this NOSI will not be considered for the NOSI initiative.
Janet Kuramoto-Crawford, PhD
National Institute on Drug Abuse (NIDA), Division of Epidemiology, Services and Prevention Research (DESPR)
Telephone: (301) 443-8856